{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(30)"],"submitter":["Kimura M"],"pubmed_abstract":["We previously reported the establishment of several types of long-term estrogen-depleted-resistant (EDR) cell lines from MCF-7 breast cancer cells. Type 1 EDR cells exhibited the best-studied mechanism of aromatase inhibitor (AI) resistance, in which estrogen receptor (ER) expression remained positive and PI3K signaling was upregulated. Type 2 EDR cells showed reduced ER activity and upregulated JNK-related signaling. The mTOR inhibitor everolimus reduced growth in cells similar to Type 1 EDR cells. The present study generated everolimus-resistant (EvR) cells from Types 1 and 2 EDR cells following long-term exposure to everolimus <i>in vitro</i>. These EvR cells modeled resistance to AI and everolimus combination therapies following first-line AI treatment failure. In Type 1 EvR cells, eve"],"journal":["Oncotarget"],"pagination":["21468-21477"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5940386"],"repository":["biostudies-literature"],"pubmed_title":["Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer."],"pmcid":["PMC5940386"],"pubmed_authors":["Niwa T","Kaneko Y","Hayashi SI","Endo I","Narui K","Yamaguchi Y","Kimura M","Hanamura T","Tsuboi K"],"additional_accession":[]},"is_claimable":false,"name":"Acquired resistance to everolimus in aromatase inhibitor-resistant breast cancer.","description":"We previously reported the establishment of several types of long-term estrogen-depleted-resistant (EDR) cell lines from MCF-7 breast cancer cells. Type 1 EDR cells exhibited the best-studied mechanism of aromatase inhibitor (AI) resistance, in which estrogen receptor (ER) expression remained positive and PI3K signaling was upregulated. Type 2 EDR cells showed reduced ER activity and upregulated JNK-related signaling. The mTOR inhibitor everolimus reduced growth in cells similar to Type 1 EDR cells. The present study generated everolimus-resistant (EvR) cells from Types 1 and 2 EDR cells following long-term exposure to everolimus <i>in vitro</i>. These EvR cells modeled resistance to AI and everolimus combination therapies following first-line AI treatment failure. In Type 1 EvR cells, eve","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2025-04-05T10:57:21.697Z","creation":"2019-03-26T23:37:40Z"},"accession":"S-EPMC5940386","cross_references":{"pubmed":["29765553"],"doi":["10.18632/oncotarget.25133"]}}